scholarly journals Participation of glutamatergic and nitrergic systems in the striatal dopamine release induced by isatin, a MAO inhibitor

2021 ◽  
Author(s):  
Lilian R.F. Faro ◽  
Lorenzo Justo ◽  
Raquel Gómez ◽  
Rafael Durán
Keyword(s):  
Dopamine Release ◽  
Striatal Dopamine ◽  
Mao Inhibitor ◽  
Striatal Dopamine Release

Effects and mechanism of action of isatin, a MAO inhibitor, on in vivo striatal dopamine release

2016 ◽  
Vol 99 ◽  
pp. 147-157 ◽  
Author(s):  
Lorenzo Antonio Justo ◽  
Rafael Durán ◽  
Miguel Alfonso ◽  
Daniel Fajardo ◽  
Lilian Rosana F. Faro
Keyword(s):  
Mechanism Of Action ◽  
Dopamine Release ◽  
Striatal Dopamine ◽  
Mao Inhibitor ◽  
Striatal Dopamine Release

VENTRAL STRIATAL DOPAMINE RELEASE AND SENSORIMOTOR GATING

1998 ◽  
Vol 9 (Supplement) ◽  
pp. S95
Author(s):  
L. S. Wilkinson ◽  
T. Humbya ◽  
M. A. Geyer
Keyword(s):  
Dopamine Release ◽  
Sensorimotor Gating ◽  
Striatal Dopamine ◽  
Striatal Dopamine Release

scholarly journals Glycine stimulates striatal dopamine release in conscious rats

1993 ◽  
Vol 110 (1) ◽  
pp. 50-53 ◽  
Author(s):  
Gal Yadid ◽  
Karel Pacak ◽  
Eliahu Golomb ◽  
Judith D. Harvey-White ◽  
Daniel M. Lieberman ◽  
...  
Keyword(s):  
Dopamine Release ◽  
Striatal Dopamine ◽  
Conscious Rats ◽  
Striatal Dopamine Release

scholarly journals Depopulation of α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson’s disease model

2018 ◽  
Author(s):  
Michal Wegrzynowicz ◽  
Dana Bar-On ◽  
Laura Calo’ ◽  
Oleg Anichtchik ◽  
Mariangela Iovino ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cell Death ◽  
Dopaminergic Neurons ◽  
Dopamine Release ◽  
Striatal Dopamine ◽  
Substantia Nigra Pars Compacta ◽  
Motor Deficit ◽  
Promising Therapeutic Approach ◽  
Striatal Dopamine Release

SUMMARYParkinson’s Disease (PD) is characterized by the presence of α-synuclein aggregates known as Lewy bodies and Lewy neurites, whose formation is linked to disease development. The causal relation between α-synuclein aggregates and PD is not well understood. We generated a new transgenic mouse line (MI2) expressing human, aggregation-prone truncated 1-120 α-synuclein under the control of the tyrosine hydroxylase promoter. MI2 mice exhibit progressive aggregation of α-synuclein in dopaminergic neurons of the substantia nigra pars compacta and their striatal terminals. This is associated with a progressive reduction of striatal dopamine release, reduced striatal innervation and significant nigral dopaminergic nerve cell death starting from 6 and 12 months of age, respectively. Overt impairment in motor behavior was found in MI2 mice at 20 months of age, when 50% of dopaminergic neurons are lost. These changes were associated with an increase in the number and density of 20-500nm α-synuclein species as shown by dSTORM. Treatment with the oligomer modulator anle138b, from 9-12 months of age, restored striatal dopamine release and prevented dopaminergic cell death. These effects were associated with a reduction of the inner density of α-synuclein aggregates and an increase in dispersed small α-synuclein species as revealed by dSTORM. The MI2 mouse model recapitulates the progressive dopaminergic deficit observed in PD, showing that early synaptic dysfunction precedes dopaminergic axonal loss and neuronal death that become associated with a motor deficit upon reaching a certain threshold. Our data also provide new mechanistic insight for the effect of anle138b’s function in vivo supporting that targeting α-synuclein aggregation is a promising therapeutic approach for PD.

Sign in / Sign up

Export Citation Format

Share Document